Our Stroke portfolio delivers life-saving interventional solutions for patients with ischemic stroke for the best chance of a full recovery.
Our Vascular portfolio is transforming thrombectomy care for people suffering from devastating vascular diseases, including venous thromboembolism and acute limb ischemia.
We are developing the Telos robotic platform* to expand access to lifesaving care through purposeful design and innovation.
*Currently in development. Not approved for use or available for sale.
Imperative Care is addressing gaps across the entire patient journey to elevate care for patients suffering from stroke and other devastating vascular diseases.
Back to News
July 25, 2024
Imperative Care Completes Initial Closing of Series E Financing for up to $150 Million; Shacey Petrovic Appointed to Vice Chair, Board of Directors
July 24, 2024
Imperative Care Announces Clinical Data from the Pivotal Imperative Trial Evaluating the Zoom Reperfusion System for the Treatment of Ischemic Stroke
July 18, 2024
Imperative announces US FDA clearance and initial cases with “first” stroke-specific insert catheters
July 17, 2024
Imperative Care Announces FDA Clearance and Initial Cases of the Zoom 6F Insert Catheters, the First Insert Catheters Built for Stroke
July 8, 2024
Statement on Intellectual Property Litigation
January 29, 2024
Imperative Care Announces Four Senior Leadership Appointments
Media Contact
Rigo Magana
Corporate Communications
rmagana@imperativecare.com
Investor Contact
Phil Nalbone
VP of Corporate Development and Investor Relations
pnalbone@imperativecare.com
Contact us
